Нет интернет-соединения — показывается сохранённая версия страницы.

Axsome Therapeuti…

USUSD
← К скринеру
US:AXSMLSE:0HKF

Axsome Therapeutics Inc (US:AXSM) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.

О компании

Сайт
axsome.com
Сектор
Health Care · Biotechnology: Pharmaceutical Preparations
Штаб-квартира
New York City, United States
Генеральный директор
Dr. Herriot Tabuteau M.D.
Сотрудники
1 346
Основана
2012
Акций в обращении
52.38 млн на 2026-08-03
Свободное обращение
44.46 млн
Рыночная капитализация
9.75 млрд USD
Инсайдеры
15.08%
Институциональные инвесторы
74.6%
Отрасль (SIC)
Pharmaceutical Preparations
ISIN
US05464T1043
LEI
549300EXGR0XLRJEIB95
Описание

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Биржи и тикеры

БиржаТикерВалютаЦенаТип
US USA StocksAXSM основнойUSD170.08 -1.67%обыкновенные акции
LSE London Stock Exchange0HKF IOBUSD197.28 +0.00%обыкновенные акции

Цена за 3 месяца

день роста день падения экс-дата дивиденда дата выплатыНаведите / коснитесь дня — цены открытия, закрытия, максимальная и минимальная

Дивиденды

Выплаты дивидендов не обнаружены (проверено 09.10.2026). Компания, вероятно, не выплачивает дивиденды.

Новости этой недели

Новостей с сайта компании пока нет.

реклама

Крупнейшие держатели

ДержательДоляАкцииДата отчета
TABUTEAU HERRIOT (Chief…≈14.05%7.35 млн2026-08-06
Blackrock Inc.5.93%3.1 млн2026-06-30
Vanguard Portfolio Manag…3.79%1.98 млн2026-06-30
Vanguard Capital Managem…3.75%1.97 млн2026-06-30
Invesco Ltd.3.19%1.67 млн2026-06-30
FMR, LLC2.94%1.54 млн2026-06-30
VANGUARD INDEX FUNDS-Van…2.65%1.39 млн2026-06-30
VANGUARD INDEX FUNDS-Van…1.92%1 млн2026-06-30
Geode Capital Management…1.85%967 1722026-06-30
Morgan Stanley1.54%804 0822026-06-30
State Street Corporation1.5%785 6612026-06-30
Deep Track Capital, Lp1.34%700 0002026-06-30
Two Sigma Investments, L…1.28%669 4782026-06-30
VANGUARD INDEX FUNDS-Van…1.1%578 2332026-06-30
VANGUARD INDEX FUNDS-Van…0.95%495 7622026-06-30
AIM Counselor Series TRT…0.89%468 5392026-05-31
COLEMAN MARK H (Director…≈0.83%434 2452026-06-10
Delaware Group Equity Fu…0.82%430 2502026-05-31
First TRT Exch-Trd Fd.-F…0.74%387 2412026-08-31
Vanguard Explorer Fund0.7%365 4332026-04-30
iShares Trust-iShares Bi…0.62%322 4202026-08-31
Franklin Custodian Funds…0.57%300 0002026-06-30
JEFFS ROGER A (Director)≈0.11%58 3672026-06-11
PIZZIE NICK (Chief Finan…≈0.08%43 3552026-06-09
SAAD MARK E (Director)≈0.02%11 7312026-06-08
MAHONY SUSAN M (Director…≈0%8292026-06-10
JACOBSON MARK L (Chief O…—02026-09-03
MAIZEL ARI (Officer)—02026-04-22
MURDOCK HUNTER R (Genera…—02025-06-23